1.Molecular targeting for treatment of advanced hepatocellular carcinoma.
The Korean Journal of Hepatology 2009;15(3):299-308
Hepatocellular carcinoma (HCC) is a major global health problem, which has a grave morbidity and mortality. Over the past few decades, no effective systemic therapeutic modalities have been established for patients with the unresectable HCC in advanced stage. Sorafenib is a small molecule that blocks cancer cell proliferation by targeting the intracellular signaling pathway at the level of Raf-1 and B-Raf serine-threonine kinases, and exerts an anti-angiogenic effect by targeting the vascular endothelial growth factor receptor-1, 2 and 3, and platelet-derived growth factor receptor-beta tyrosine kinases. Recently, two clinical successful applications, SHARP and Asia-Pacific trial, of multikinase inhibitor sorafenib represent a significant advance in the treatment of advanced HCC patients without a curative chance. However, because the results of clinical trials show diverse responses in a subset of HCC patients, a molecular classification of HCC through the excavation of specific biomarkers related to its biological behavior is necessary for sorting HCC patients to each group with a biological homogeneity, ultimately leading to the most suitable individualization of molecular targeted therapy in HCC.
Antineoplastic Agents/therapeutic use
;
Benzenesulfonates/therapeutic use
;
Carcinoma, Hepatocellular/pathology/secondary/*therapy
;
Humans
;
Liver Neoplasms/blood supply/pathology/*therapy
;
Neovascularization, Pathologic
;
Proto-Oncogene Proteins B-raf/antagonists & inhibitors/metabolism
;
Proto-Oncogene Proteins c-raf/antagonists & inhibitors/metabolism
;
Pyridines/therapeutic use
;
Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors/metabolism
;
Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors/metabolism
;
Signal Transduction
2.The design of muti-target antitumor drugs affecting on FTase and Raf-1 kinase.
Juan ZHAO ; Yi-jing ZHU ; Lu ZENG ; Qian WANG ; Feng-chao JIANG
Acta Pharmaceutica Sinica 2011;46(2):170-178
Ras/Raf/MEK/ERK singal transduction plays an important role in cell proliferation, differentiation, apoptosis, metastasis and metabolism. This investigation focused on this signal pathway and chose farnesyl transferase (FTase) as the main target and Raf-1 kinase as the second target. A lot of compounds were selected to construct the pharmacophore models of farnesyl transferase inhibitors (FTIs) and Raf-1 kinase inhibitors by using computer-aided drug design (CADD). The pharmacophore of FTIs is constituted by a hydrogen bonding acceptor, an aromatic ring, a positive ionizable and two hydrophobic regions; the pharmacophore of Raf-1 kinase is constituted by a hydrogen donor, a hydrogen acceptor, a hydrophobic regions and an aromatic ring. There are some similarities between the two pharmacophores. After analysis of the constructions of these two pharmacophores, some new aminomethylbenzoic acid derivatives with good forecasting activity against both of FTase and Raf-1 kinase were designed with these new pharmacophore models.
Antineoplastic Agents
;
chemical synthesis
;
chemistry
;
pharmacology
;
Computer-Aided Design
;
Drug Delivery Systems
;
Drug Design
;
Enzyme Inhibitors
;
chemical synthesis
;
chemistry
;
Farnesyltranstransferase
;
antagonists & inhibitors
;
Molecular Structure
;
Proto-Oncogene Proteins c-raf
;
antagonists & inhibitors
;
Signal Transduction
3.Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma.
Yu-Sui CHANG ; Ji-Chun LIU ; Hua-Qun FU ; Ben-Tong YU ; Shu-Bing ZOU ; Qi-Cai WU ; Li WAN
Acta Pharmaceutica Sinica 2013;48(5):635-641
Ras is best known for its ability to regulate cell growth, proliferation and differentiation. Mutations in Ras are associated with the abnormal cell proliferation which can result in incidence of all human cancers. Extracellular signal-regulated kinase (ERK) is a downstream effector of Ras and plays important roles in prognosis of tumors. Recently, evidence has gradually accumulated to demonstrate that there are other effectors between Ras and ERK, these proteins interact each other and constitute the thorough Ras/Raf/MEK/ERK signaling pathway. The pathway has profound effects on incidence of esophageal carcinoma and clinical applications of some chemotherapeutic drugs targeting the pathway. Further understanding of the relevant molecular mechanisms of Ras/Raf/MEK/ERK signaling pathway can be helpful for the development of efficient targeting therapeutic approaches which contribute to the treatment of esophageal cancer. In this article, roles of Ras/Raf/MEK/ERK signaling pathway in esophageal carcinoma as well as pharmacological targeting point in the pathway are reviewed.
Animals
;
Antineoplastic Agents
;
pharmacology
;
therapeutic use
;
Carcinoma, Squamous Cell
;
drug therapy
;
enzymology
;
pathology
;
Cell Line, Tumor
;
Enzyme Activation
;
drug effects
;
Esophageal Neoplasms
;
drug therapy
;
enzymology
;
pathology
;
Extracellular Signal-Regulated MAP Kinases
;
antagonists & inhibitors
;
metabolism
;
Humans
;
Mitogen-Activated Protein Kinase Kinases
;
antagonists & inhibitors
;
metabolism
;
Proto-Oncogene Proteins c-raf
;
antagonists & inhibitors
;
metabolism
;
Signal Transduction
;
drug effects
;
ras Proteins
;
antagonists & inhibitors
;
metabolism
4.Anticancer effect of 17-(6-cinnamamido-hexylamino-)-17-demethoxygeldanamycin: in vitro and in vivo.
Liang LI ; Hong LIU ; Sheng-Hua ZHANG ; Lei HU ; Yong-Su ZHEN
Acta Pharmaceutica Sinica 2013;48(12):1771-1777
In the present study, a new compound named 17-(6-cinnamamido-hexylamino-)-17-demethoxygeldanamycin (CDG) was obtained by introducing the cinnamic acid (CA) group into the 17-site of geldanamycin (GDM). The anti-cancer effects of CDG in vitro and in vivo were evaluated. MTT assay was used to examine the inhibitory effect of CDG on the proliferation of MCF-7, HepG2, H460 and SW1990 cells. Immunofluorescent staining flow cytometry combined with Annexin V-FITC/PI staining were used to detect apoptotic cells. Transwell assay was used to analyze the effect of CDG on cell invasion and migration ability. Western blotting was used to detect the expression levels of RAF-1, EGFR, AKT, CDK4 and HER-2 of MCF-7, HepG2 and H460 cells. The toxicities of CDG and GDM were evaluated in mice. Using the subcutaneously transplanted MCF-7 xenograft in nude mice, inhibitory effect was evaluated in vivo. The results showed that CDG inhibited the proliferation of cancer cells (IC50: 13.6-67.4 microg.mL-1). After exposure to CDG for 48 h, most cells presented typical morphologic changes of apoptosis such as chromatin condensation or shrunken nucleus. The rates of apoptosis of MCF-7, HepG2, H460 and SW1990 cells incubated with 10 microg.mL-1 CDG were 23.16%, 27.55%, 22.21%, 20.47%, respectively. A dose-dependent reduction of migration of four cell lines was found after exposure to CDG. The decreased levels of RAF-1, EGFR, AKT, CDK4 and HER-2 showed that CDG possessed HSP90 inhibitory effect. The result of animal toxicity test on the mice suggested that CDG had lower toxicity than GDM. Meanwhile, CDG inhibited the growth of MCF-7 xenografts of athymic mice.
Animals
;
Antineoplastic Agents
;
chemical synthesis
;
chemistry
;
pharmacology
;
Apoptosis
;
drug effects
;
Benzoquinones
;
chemical synthesis
;
chemistry
;
pharmacology
;
Cell Line, Tumor
;
Cell Movement
;
drug effects
;
Cell Proliferation
;
drug effects
;
Cyclin-Dependent Kinase 4
;
metabolism
;
Female
;
HSP90 Heat-Shock Proteins
;
antagonists & inhibitors
;
Humans
;
Lactams, Macrocyclic
;
chemical synthesis
;
chemistry
;
pharmacology
;
Male
;
Mice
;
Mice, Inbred BALB C
;
Mice, Nude
;
Neoplasm Invasiveness
;
Neoplasm Transplantation
;
Proto-Oncogene Proteins A-raf
;
metabolism
;
Proto-Oncogene Proteins c-akt
;
metabolism
;
Random Allocation
;
Receptor, Epidermal Growth Factor
;
metabolism
;
Receptor, ErbB-2
;
metabolism
;
Tumor Burden
;
drug effects
;
Xenograft Model Antitumor Assays